

2015 .

Оглавление

.....	3
.....	4
-10.....	4
.....	4
.....	4
.....	5
.....	6
.....	6
.....	7
.....	7
.....	9
.....	9
.....	10
.....	13
.....	13
.....	13
.....	14

XVIII
2015 .

» 14

:

.

.

/

/

EMBASE MEDLINE,

(.1).

1.

1	1	
1b	« »	()
1	, /	« »
2	>2	()
2b	« »	(<80% , ; . . .)
2		« »;
3	3b	« - »
3b		« -

	«	»
4	- « »	(« - »)
5	, «	, « »
D	1 4 4	1 2 3 2 3

http://www.cebm.net/levels_of_evidence.asp#refs.

() –

.

-10

51 –

.

51.0 –

()

.

51.1 –

()

.

51.2 –

()

.

51.3 –

()

.

51.9 –

.

1 4

100 000

(1-3),

15-20%

.

)

(

,

,

,

-
- (,)
- ()
)

- (,)
- : (1), (1
).

6
(PUCAI)

-
-
-
- ((/) 7-14).
- (

3 , ,
14-16).

(PUCAI<10).

- () -

• (4) (2 6)

• ,

•

•

• (, , , ,
.)

• /

•

•

•

:

_____ :

• 1-2 ,

,

« » , ,

• ,

.

• .

• 20-50 ,

• ,

•

• .

,
 :
 -
 - (),
 (), , - ()
 - *Clostridium difficile* ,
 3
 - (p-ANCA)
 - (ASCA).
 - :
 - (:
 (),
 ,)
 - ()
 - () ()
)
 :
 -

2. (Pediatric Ulcerative Colitis)

Activity Index: PUCAI)

1.	
	0
	5
	10
2.	
	0
, 50%	10
	20

(50%)	30
3.	
	0
	5
	10
4. 24	
0-2	0
3-5	5
6-8	10
>8	15
5. (,)	
	0
	10
6.	
	0
	5
	10

PUCAI (0-85)

PUCAI

- - 10 (89%, 89%)
 - - 10-34 (95%, 95%)
 - - 35-64 (92%, 94%)
 - - 65
 - PUCAI , 20
- .
- 3.**
- ,

()	,	, <i>Clostridium difficile</i>

	3	<i>Yersinia</i>
()	,	/ IgE, (),
()	()	HLA-B5,
()	,	

● «

».

● «

)».

● «

».

(, ,).

5-

(5-)

1. (: A07EC02) (ATX: A07EC01)

5- (2b).

60 80 / (4,8 /) 2 .

5- 25 / 1 / .

70-100 / / (4 /).

50% 6,4 /

7-14

,

- ().

2. 5-

().

,

(40 / 2,4 / ;

1,2 /)

3. 2

,

()

1.

,

5- (2b).

2. (: H02AB07) / (H02AB06)

1 /

40

(.4).

4.

(/)

1	2	3	4	5	6	7	8	9	10	11
60*	50	40	35	30	25	20	15	10	5	0
50*	40	40	35	30	25	20	15	10	5	0
45*	40	40	35	30	25	20	15	10	5	0
40	40	30	30	25	25	20	15	10	5	0
35	35	30	30	25	20	15	15	10	5	0
30	30	30	25	20	15	15	10	10	5	0
25	25	25	20	20	15	15	10	5	5	0
20	20	20	15	15	12.5	10	7.5	5	2.5	0
15	15	15	12.5	10	10	7.5	7.5	5	2.5	0

2-3 : 1 / (60)

(*

60 / , 3-5 /).

(PUCAI <20) 7-14

PUCAI 20

2-3 : PUCAI 15 30

(1);

PUCAI >35:

1-2

; PUCAI >60

PUCAI 20

:

>20 , ,

1.

2.

1. ((ATX: L04AX01) 6- (:
L01BB02.))

5- (1-2

)

5- (2c).

10-14

2,5 / 1-1,5 /

6-

2.

(2c).

3. (: L04AD01) (:
L04AD02),

4

4. (: L01BA01)

1.

5-

5 / (3

0, 2 6

5 / 8

).

2. (: L04AB02)

(,).

,

,

4-8

3. (: L04AB04)

:

0 2 120

80

40

80

40

<40 ,

40

1

2

.

5- ,

(2b)

-

-

,

.

,

.

1.

,

,

2.

,

,

:

1.

· , , ,

, .

2. PUCAI <10

, 10 34 -

35 64 -

65 -

PUCAI

20

.

.

1.

2.

()

3.

4.

5.

()

:

•

1

•

1

3

•

1

2

•

(

,

,

, , , , , , ,

, , , , ,

(),

)

1

2

•

p-ANCA, ASCA

1

3

•

1

3

•

1

3

•

1

6

•

:

,

1. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. *Inflamm Bowel Dis* 2011;17:423–39.
2. Henderson P, Hansen R, Cameron FL, et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. *Inflamm Bowel Dis* 2012;18:999–1005.
3. Heyman MB, Kirschner BS, Gold BD, et al. Children with earlyonset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. *J Pediatr* 2005;146:35–40.
4. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. *Gastroenterology* 2008;135:1114–22.
5. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. *Am J Gastroenterol* 2009;104:2080–8.
6. Travis SPL, Stange EF, Le mann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. *J Crohn Colitis* 2008;2:24–62.
7. Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. *Am J Gastroenterol* 2011;106:574–88.
8. Glickman JN, Bousvaros A, Farraye FA, et al. Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. *Am J Surg Pathol* 2004;28:190–7.
9. Levine A, de Bie CL, Turner D, et al. Atypical disease phenotypes in paediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. *Inflamm Bowel Dis*. 2012 May 8. [Epub ahead of print]
10. Robert ME, Tang L, Hao LM, et al. Patterns of inflammation in mucosal biopsies of ulcerative colitis: perceived differences in pediatric populations are limited to children younger than 10 years. *Am J Surg Pathol* 2004;28:183–9.

51. Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. *J Crohns Colitis* 2011;5:13.
52. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. *Aliment Pharmacol Ther* 2009;30:210–26.
53. Chaparro M, Guerra I, Munoz-Linares P, et al. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. *Aliment Pharmacol Ther* 2012;35:971–86.
54. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. *Inflamm Bowel Dis* 2010;16:112–24.
55. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. *Am J Gastroenterol* 1993;88:227–32.
56. McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. *Gut* 1986;27:481–5.
57. Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. *Gastroenterology* 1980;79:1199–204.
58. Barabino A, Tegaldo L, Castellano E, et al. Severe attack of ulcerative colitis in children: retrospective clinical survey. *Dig Liver Dis* 2002; 34:44–9.
59. Bechtold S, Alberer M, Arenz T, et al. Reduced muscle mass and bone size in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2010;16:216–25.
60. Werkstetter KJ, Pozza SB, Filipiak-Pittroff B, et al. Long-term development of bone geometry and muscle in pediatric inflammatory bowel disease. *Am J Gastroenterol* 2011;106:988–98.
61. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. *Gastroenterology* 1998;114:902–11.
62. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. *Inflamm Bowel Dis* 2007;13:42–50.
63. Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. *J Pediatr Gastroenterol Nutr* 2006;43:42–51.
64. Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2011;53:11–25.
65. Greenley RN, Stephens M, Doughty A, et al. Barriers to adherence among adolescents with inflammatory bowel disease. *Inflamm Bowel Dis* 2010;16:36–41.
66. Hommel KA, Denson LA, Baldassano RN. Oral medication adherence and disease severity in pediatric inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2011;23:250–4.
67. Hommel KA, Baldassano RN. Barriers to treatment adherence in pediatric inflammatory bowel disease. *J Pediatr Psychol* 2010; 35:1005–10.
68. Reed-Knight B, Lewis JD, Blount RL. Association of disease, adolescent, and family factors with medication adherence in pediatric inflammatory bowel disease. *J Pediatr Psychol* 2011;36:308–17.
69. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. *Am J Gastroenterol* 2009;104:2760–7.

70. Actis GC, Fadda M, Pellicano R, et al. The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis. *Biomed Pharmacother* 2009;63:362–5.
71. Turner D, Otley AR, Mack D, et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. *Gastroenterology* 2007;133:423–32.
72. UpToDate.com